rewirebio.iobenchmarks
Configuration

Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)

Promoter fragmentation entropy (PFE), open chromatin regions, SVM: Feature setting: open chromatin regions.

6 evaluations · 33 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Model Capabilities & Hardware Requirements

Deployment facts recorded for Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024). Fields the record does not carry are marked not recorded.

ParametersNot recorded
Minimum VRAMNot recorded
Inference LatencyNot recorded
Context WindowNot recorded
AccessNot recorded
LicenseNot recorded

Evaluations and results

6 evaluations · 33 results. Different protocols are not a single leaderboard.

Sorted by AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationProtocol and datasetAUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (liver cancer vs controls; mean of 10 x 10-fold cross-validation)AUROC (liver cancer vs healthy; independent validation)AUROC (lung cancer vs healthy; independent validation)AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (lung cancer vs non-cancer; independent validation)AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (liver cancer vs healthy; independent validation)Sensitivity at 85% specificity (lung cancer vs healthy; independent validation)Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (lung cancer vs non-cancer; independent validation)Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (liver cancer vs healthy; independent validation)Sensitivity at 95% specificity (lung cancer vs healthy; independent validation)Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (lung cancer vs non-cancer; independent validation)Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2), DELFI 2019 internally cross-validated cancer detection cohort0.958 (best in column)0.9650.950.9660.962Not reportedNot reportedNot reported0.971Not reported0.9870.820.8910.7720.8720.937Not reportedNot reported0.91Not reported0.940.6160.8190.6730.7930.837Not reportedNot reported0.825Not reported0.890.523
Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 pan-cancer vs healthy, Cristiano cohort, 10 x 10-fold cross-validation (Table 1 AUC), DELFI 2019 internally cross-validated cancer detection cohort0.958 (best in column)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported
Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2), Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reported0.937Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported
Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3), Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.706Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.45Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.194Not reportedNot reported
Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Mathios et al. independent lung cohort (Table S3), Mathios et al. 2021 independent lung cohort, 46 lung cancer and 385 healthy (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.81Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.587Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.348Not reportedNot reportedNot reportedNot reported
Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3), Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reported0.766Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.5Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.375Not reportedNot reportedNot reportedNot reportedNot reported
All 33 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.965 AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9532 to 0.9759

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C14; group 'BRCA'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.891 Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8654 to 0.9159

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E14; group 'BRCA'; row 'PFE'; column 'Sensitivity @85% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.819 Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7855 to 0.8525

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D14; group 'BRCA'; row 'PFE'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.95 AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9366 to 0.9639

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C24; group 'CHOL'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.772 Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7133 to 0.8300

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E24; group 'CHOL'; row 'PFE'; column 'Sensitivity @85% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.673 Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.6075 to 0.7391

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D24; group 'CHOL'; row 'PFE'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.966 AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9556 to 0.9769

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C34; group 'CRC'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.872 Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8325 to 0.9108

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E34; group 'CRC'; row 'PFE'; column 'Sensitivity @85% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.793 Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7427 to 0.8440

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D34; group 'CRC'; row 'PFE'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2)
Dataset: Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024)
0.937 AUROC (liver cancer vs controls; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9260 to 0.9488

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Jiang cohort liver cancer cross-validation

ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C84; group 'LIHC'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.971 AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9486 to 0.9925

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C54; group 'NSCLC'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.91 Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8574 to 0.9626

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E54; group 'NSCLC'; row 'PFE'; column 'Sensitivity @85% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.825 Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7538 to 0.8962

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D54; group 'NSCLC'; row 'PFE'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.987 AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9812 to 0.9932

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C64; group 'OV'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.94 Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9082 to 0.9718. Closing bracket missing in the printed cell.

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E64; group 'OV'; row 'PFE'; column 'Sensitivity @85% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.89 Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8481 to 0.9319

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D64; group 'OV'; row 'PFE'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.82 AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.7884 to 0.8517

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C74; group 'PAAD'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.616 Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.5621 to 0.6696

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E74; group 'PAAD'; row 'PFE'; column 'Sensitivity @85% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.523 Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.4668 to 0.5798

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D74; group 'PAAD'; row 'PFE'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.958 AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9528 to 0.9631

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C4; group 'PANCAN'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.962 AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9446 to 0.9803

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C44; group 'STAD'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.937 Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9098 to 0.9635

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E44; group 'STAD'; row 'PFE'; column 'Sensitivity @85% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.837 Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7938 to 0.8795

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D44; group 'STAD'; row 'PFE'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)
0.706 AUROC (lung cancer vs non-cancer; independent validation)
unitless · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)

ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C14; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'PFE'; column 'AUC'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)
0.45 Sensitivity at 85% specificity (lung cancer vs non-cancer; independent validation)
fraction · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

PFE (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)

ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E14; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'PFE'; column 'Sensitivity @85% specificity'

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Use this configuration

How it works, versions and access

Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ctdnafrag-20261009-config-hou2024-pfe-open-chromatin.

Source locator: Article Table 1 row 'PFE', column 'open chromatin region'; Experimental Section P29-P41

Related records

How to cite

Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024). Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/ctdnafrag-20261009-config-hou2024-pfe-open-chromatin/

Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.

The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence

Suggest a correction